Switching of an inhibitor of vascular endothelial growth factor in the treatment of resistant to ranibizumab neovascular form of age-related macular degeneration. Case study
- Authors: Ivanova N.V1, Rasin O.G1, Savchenko A.V1, Litvinenko O.A2
-
Affiliations:
- Vernadsky Crimean Federal University
- “Oko-center” ltd
- Issue: Vol 9, No 3 (2016)
- Pages: 69-76
- Section: Articles
- URL: https://journals.eco-vector.com/ov/article/view/5354
- DOI: https://doi.org/10.17816/OV9369-76
- ID: 5354
Cite item
Abstract
Full Text
About the authors
Nanuli V Ivanova
Vernadsky Crimean Federal University
Email: azarkonf@mail.ru
MD, PhD, Professor, Head of Department of Ophthalmology
Oleg G Rasin
Vernadsky Crimean Federal University
Email: ol61@mail.ru
PhD, Associate Professor, Department of Ophthalmology
Aleksey V Savchenko
Vernadsky Crimean Federal University
Email: sav_07@bk.ru
Assistant of the Department of Ophthalmology
Olga A Litvinenko
“Oko-center” ltd
Email: yasan07@mail.ru
ophthalmologist
References
- Бикбов М.М. Оперативное лечение высокой отслойки пигментного эпителия сетчатки на фоне возрастной макулярной дегенерации // Современные технологии в офтальмологии. - 2016. - № 1. - С. 38-40. [Bikbov MM. Operativnoe lechenie vysokoj otslojki pigmentnogo jepitelija setchatki na fone vozrastnoj makuljarnoj degeneracii. Sovremennye tehnologii v oftal’mologii. 2016(1):38-40. (In Russ).]
- Инструкция по применению лекарственного препарата для медицинского применения ЭЙЛЕА ЛП-003544 от 29.03.2016. [Instrukcija po primeneniju lekarstvennogo preparata dlja medicinskogo primenenija JeJLEA LP-003544 ot 29.03.2016. (In Russ).]
- Инструкция по применению лекарственного препарата для медицинского применения Луцентис № ЛСР-004567/08 от 13.08.2015. [Instrukcija po primeneniju lekarstvennogo preparata dlja medicinskogo primenenija Lucentis No LSR-004567/08, 13.08.2015. (In Russ).]
- Диагностика и лечение возрастной макулярной дегенерации: Федеральные клинические рекомендации. - М., 2013. [Diagnostika i lechenie vozrastnoj makuljarnoj degeneracii: Federal’nye klinicheskie rekomendacii. Moscow; 2013. (In Russ).]
- Hyung C, et al. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Downloaded from http: //bjo.bmj.com/on March 20, 2016. Published by group.bmj.com.
- Brown D, Heier JS, Ciulla T, et al. CLEAR-IT 2 Investigators. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011;118(6):1089-1097. doi: 10.1016/j.ophtha.2011.02.039.
- Congdon N, O’Colmain B, Klaver CC, et al. Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122 (4):477-485. doi: 10.1001/archopht.122.4.477.
- Introini U. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence. Graefes Arch Clin Exp Ophthalmol. 2012;250:1283-1292. doi: 10.1007/s00417-012-1955-2.
- Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606-2617. doi: 10.1056/NEJMra0801537.
- Packo KH. Initial experience with aflibercept in the management of patients with persistent exudation due to AMD undergoing chronic ranibizumab therapy. Presented at: American Society of Retina Specialists Annual Scientific Meeting; August 25-29, 2012; Las Vegas, NV.
- Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185. doi: 10.1007/s10456-011-9249-6.
- Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2000. Bull World Health Organ. 2004;82(11):844-851.
- Shah CP. Aflibercept for exudative AMD suboptimally responsive to ranibizumab and bevacizumab. Presented at: American Society of Retina Specialists Annual Scientific Meeting; August 25-29, 2012; Las Vegas, NV.